QDISS Stud: QD Isentress as Switch Strategy in Virologically Suppressed HIV-1 Infected-Patient (QDISS)
QD Isentress as Switch Strategy in Virologically Suppressed HIV-1 Infected-Patient
Sponsor: Nantes University Hospital
Listed as NCT03195452, this PHASE2 trial focuses on Virus-HIV and remains completed. Sponsored by Nantes University Hospital, it has been updated 10 times since 2017, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 5 earlier versions
-
Nov 2019 — Jun 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2019 — Nov 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — Jan 2019 [monthly]
Recruiting PHASE2
-
Dec 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Aug 2017 — Dec 2017 [monthly]
Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Nantes University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bordeaux, France , La Roche-sur-Yon, France , Le Mans, France , Lyon, France , Montpellier, France , Nantes, France , Nice, France , Orléans, France , Paris, France , Reims, France and 2 more locations